Cargando…

Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy

INTRODUCTION: Exosomes are important mediators of intercellular communication. Previously, we characterized circulating exosomal miR-425-3p as a non-invasive prognostic marker for predicting clinical response to platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yuzhu, Yuwen, Daolu, Chen, Jingwei, Zheng, Bingfeng, Gao, Jian, Fan, Minmin, Xue, Wenwen, Wang, Yixuan, Li, Wuhao, Shu, Yongqian, Xu, Qiang, Shen, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790351/ https://www.ncbi.nlm.nih.gov/pubmed/31632022 http://dx.doi.org/10.2147/IJN.S221383

Ejemplares similares

Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC
por: Tang, Zuxiong, et al.
Publicado: (2021)

Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells
por: Zheng, Peiming, et al.
Publicado: (2017)

Inhaled Cisplatin for NSCLC: Facts and Results
por: Kosmidis, Christoforos, et al.
Publicado: (2019)

Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer
por: Fan, Minmin, et al.
Publicado: (2022)

CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging
por: Zhang, Tao, et al.
Publicado: (2021)

Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
por: Yang, Daolu, et al.
Publicado: (2021)

SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner
por: Lv, Hong-Wei, et al.
Publicado: (2021)

YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC
por: Cui, Yanwei, et al.
Publicado: (2020)

Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids
por: Han, Yi, et al.
Publicado: (2022)

Exosome‐transmitted miR‐769‐5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53
por: Jing, Xinming, et al.
Publicado: (2022)

MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway
por: Lin, Zhilai, et al.
Publicado: (2020)

Exosome-Reversed Chemoresistance to Cisplatin in Non-Small Lung Cancer Through Transferring miR-613
por: Li, Delong, et al.
Publicado: (2020)

Pre-incubation with hucMSC-exosomes prevents cisplatin-induced nephrotoxicity by activating autophagy
por: Wang, Bingying, et al.
Publicado: (2017)

Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis
por: Zhan, Haibo, et al.
Publicado: (2022)

Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2
por: Wang, Dongliang, et al.
Publicado: (2021)

Exosomal transfer of miR‐106a‐5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma
por: Li, Jiaxing, et al.
Publicado: (2021)

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy
por: Kryczka, Jolanta, et al.
Publicado: (2021)

Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner
por: Qin, Xiaobing, et al.
Publicado: (2017)

Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells
por: Luo, Yanwei, et al.
Publicado: (2020)

Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma
por: Zhang, Kun, et al.
Publicado: (2020)

Autophagy in Cisplatin Nephrotoxicity during Cancer Therapy
por: Hu, Xiaoru, et al.
Publicado: (2021)

Is Autophagy Always a Barrier to Cisplatin Therapy?
por: Xu, Jingwen, et al.
Publicado: (2022)

Increased Autophagy Levels Mediate Cisplatin Resistance in Cisplatin-Resistant Cells While Also Rendering Them Vulnerable to Autophagy Induction
por: Duan, Guihua, et al.
Publicado: (2018)

Retraction: Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma
Publicado: (2022)

Cancer cell-derived exosomal miR-425-3p induces white adipocyte atrophy
por: Liu, Anwen, et al.
Publicado: (2022)

Exosome mediated miR-155 delivery confers cisplatin chemoresistance in oral cancer cells via epithelial-mesenchymal transition
por: Kirave, Prathibha, et al.
Publicado: (2020)

Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
por: Zang, Shuzhi, et al.
Publicado: (2019)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Advanced bioinformatic analysis and pathway prediction of NSCLC cells upon cisplatin resistance
por: Hossian, A K M Nawshad, et al.
Publicado: (2021)

Proteomic profiling of extracellular vesicles and particles reveals the cellular response to cisplatin in NSCLC
por: Xu, Jiaqi, et al.
Publicado: (2021)

FRI425 BIUXX
por: Mendonça Macedo, Daniel, et al.
Publicado: (2023)

Expression of Concern: Exosomes function as nanoparticles to transfer miR-199a-3p to reverse chemoresistance to cisplatin in hepatocellular carcinoma
Publicado: (2022)

Persistent Activation of Autophagy After Cisplatin Nephrotoxicity Promotes Renal Fibrosis and Chronic Kidney Disease
por: Fu, Ying, et al.
Publicado: (2022)

Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
por: Gąsiorkiewicz, Bartosz Mateusz, et al.
Publicado: (2020)

Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun
por: Huang, Gang, et al.
Publicado: (2017)

Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
por: Garrido, Pilar, et al.
Publicado: (2017)

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
por: Gao, Jing, et al.
Publicado: (2016)

Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin
por: Takahashi, Ryosuke, et al.
Publicado: (2023)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_irl0fe0ms5mrcbdrfq2kebrtmi